LB Pharmaceuticals Files for IPO

MT Newswires Live

Sep 10, 2025

LB Pharmaceuticals filed a registration statement with the US Securities and Exchange Commission on Tuesday for an initial public offering of about 16.7 million shares of common stock, with an expected price range of $14 to $16 per share.

The company said it granted underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price.

LB Pharmaceuticals said it expects net proceeds from the offering to reach about $228.5 million, or $263.4 million if additional shares are fully exercised, with plans to use the funds to develop its lead drug LB-102 as a treatment for schizophrenia and bipolar depression and the remainder for general corporate purposes.

The company plans to list its shares on Nasdaq under the LBRX ticker.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566261786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566261786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566261786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566261786","market":"fut","top_or_hot":-1,"title":"LB Pharmaceuticals Files for IPO","media":"MT Newswires Live","content":"<html><body><p> LB Pharmaceuticals filed a registration statement with the US Securities and Exchange Commission on Tuesday for an initial public offering of about 16.7 million shares of common stock, with an expected price range of $14 to $16 per share.</p><p>The company said it granted underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price.</p><p>LB Pharmaceuticals said it expects net proceeds from the offering to reach about $228.5 million, or $263.4 million if additional shares are fully exercised, with plans to use the funds to develop its lead drug LB-102 as a treatment for schizophrenia and bipolar depression and the remainder for general corporate purposes.</p><p>The company plans to list its shares on Nasdaq under the LBRX ticker.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LB Pharmaceuticals Files for IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLB Pharmaceuticals Files for IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-10 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LB Pharmaceuticals filed a registration statement with the US Securities and Exchange Commission on Tuesday for an initial public offering of about 16.7 million shares of common stock, with an expected price range of $14 to $16 per share.</p><p>The company said it granted underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price.</p><p>LB Pharmaceuticals said it expects net proceeds from the offering to reach about $228.5 million, or $263.4 million if additional shares are fully exercised, with plans to use the funds to develop its lead drug LB-102 as a treatment for schizophrenia and bipolar depression and the remainder for general corporate purposes.</p><p>The company plans to list its shares on Nasdaq under the LBRX ticker.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LBRX","symbol_name":"LB Pharmaceuticals Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566261786","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566261786","pubTimestamp":1757442434,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LB Pharmaceuticals filed a registration statement with the US Securities and Exchange Commission on Tuesday for an initial public offering of about 16.7 million shares of common stock, with an expected price range of $14 to $16 per share.The company said it granted underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price.LB Pharmaceuticals said it expects net proceeds from the offering to reach about $228.5 million, or $263.4 million if additional shares are fully exercised, with plans to use the funds to develop its lead drug LB-102 as a treatment for schizophrenia and bipolar depression and the remainder for general corporate purposes.The company plans to list its shares on Nasdaq under the LBRX ticker.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LBRX":"LB Pharmaceuticals Inc","BK4233":"房地产运营公司","LB":"LandBridge Co. LLC","BK4213":"石油与天然气的勘探与生产"},"translate_title":"LB制药申请首次公开募股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LB":1,"LBRX":1},"content_text":"LB Pharmaceuticals filed a registration statement with the US Securities and Exchange Commission on Tuesday for an initial public offering of about 16.7 million shares of common stock, with an expected price range of $14 to $16 per share.The company said it granted underwriters a 30-day option to buy up to 2.5 million additional shares at the IPO price.LB Pharmaceuticals said it expects net proceeds from the offering to reach about $228.5 million, or $263.4 million if additional shares are fully exercised, with plans to use the funds to develop its lead drug LB-102 as a treatment for schizophrenia and bipolar depression and the remainder for general corporate purposes.The company plans to list its shares on Nasdaq under the LBRX ticker.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}